Elena Shinderman-Maman

Elena Shinderman-Maman

Auto-generated profile, based on publicly available information

Elena Shinderman-Maman

Schneider Children's Medical Center 2 Petach Tikva

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
NGNurit Gal-Mark
Nurit Gal-Mark
AGAssaf Grunwald
Assaf Grunwald
VGValid Gahramanov
Valid Gahramanov
MHMichal Hameiri-Grossman
Michal Hameiri-Grossman
ESElena Shinderman-Maman
Elena Shinderman-Maman
EBEsther R. Berko
Esther R. Berko
Purpose: Liquid biopsy monitoring in pediatric solid tumors is limited by low mutational burden and lack of trackable genomic drivers. We sought to develop a mutation-agnostic, methylation-based liquid biopsy framework enabling universal molecular surveillance of high-risk neuroblastoma. Experimental Design: Using whole-genome Oxford Nanopore Technologies sequencing of high-risk neuroblastoma tumors, we compared tumor-derived methylation profiles to a comprehensive atlas of normal human cell types and identified 72 neuroblastoma-specific differentially methylated regions (meNBLs) that were reliably detectable in cfDNA. Marker robustness and specificity were validated using independent neuroblastoma methylation datasets and assessed against methylation profiles from other cancer types. We established neuroblastoma as a distinct methylation entity within the reference atlas by integrating a panel of 25 meNBLs, enabling quantitative estimation of tumor-derived cfDNA. Assay performance was evaluated across diagnostic, remission, relapse, and healthy control samples and compared with mutation- and copy number–based approaches. Results: Neuroblastoma-derived cfDNA was consistently detected at diagnosis and relapse, but was absent in healthy controls and during confirmed remission. Methylation-based deconvolution demonstrated high specificity, with no detectable background signal in controls, and improved performance relative to copy number–based tumor fraction estimation. Longitudinal profiling enabled early molecular detection of relapse and reliable disease monitoring. Conclusions: We establish a robust, mutation-independent methylation-based liquid biopsy strategy for neuroblastoma that enables accurate, quantitative disease monitoring across all high-risk patients including those lacking trackable genomic alterations. This approach supports clinical translation of methylation-based cfDNA deconvolution as a broadly applicable platform for pediatric precision oncology.

15 September 2026
Verified
Other
Open access
NGNurit Gal-Mark
Nurit Gal-Mark
AGAssaf Grunwald
Assaf Grunwald
VGValid Gahramanov
Valid Gahramanov
MHMichal Hameiri-Grossman
Michal Hameiri-Grossman
ESElena Shinderman-Maman
Elena Shinderman-Maman
EBEsther R. Berko
Esther R. Berko
Supplementary Table S8: List of 188 neuroblastoma-specific DMRs identified by comparison with a normal human cell-type methylation atlas including and excluding neuronal tissues (13).

15 September 2026
Verified
Other
Open access
NGNurit Gal-Mark
Nurit Gal-Mark
AGAssaf Grunwald
Assaf Grunwald
VGValid Gahramanov
Valid Gahramanov
MHMichal Hameiri-Grossman
Michal Hameiri-Grossman
ESElena Shinderman-Maman
Elena Shinderman-Maman
EBEsther R. Berko
Esther R. Berko
Supplementary Table S7: Gene Ontology (GO) enrichment analysis performed on 152 neuroblastoma DMRs that were identified in comparison to all tissue types in the human reference atlas (including neurons) (13).

15 September 2026
Verified
Other
Open access
NGNurit Gal-Mark
Nurit Gal-Mark
AGAssaf Grunwald
Assaf Grunwald
VGValid Gahramanov
Valid Gahramanov
MHMichal Hameiri-Grossman
Michal Hameiri-Grossman
ESElena Shinderman-Maman
Elena Shinderman-Maman
EBEsther R. Berko
Esther R. Berko
Supplementary Table S5: Advanced tumor samples from O’Neill et al. (17) ONT cohort used for methylation comparison with neuroblastoma DMRs (n = 72)

15 September 2026
Verified
Other
Open access
NGNurit Gal-Mark
Nurit Gal-Mark
AGAssaf Grunwald
Assaf Grunwald
VGValid Gahramanov
Valid Gahramanov
MHMichal Hameiri-Grossman
Michal Hameiri-Grossman
ESElena Shinderman-Maman
Elena Shinderman-Maman
EBEsther R. Berko
Esther R. Berko
Supplementary Table S4: List of 60 neuroblastoma-associated genes from published studies analyzed for genomic aberrations in seven neuroblastoma tumors

15 September 2026
Verified
Other
Open access
NGNurit Gal-Mark
Nurit Gal-Mark
AGAssaf Grunwald
Assaf Grunwald
VGValid Gahramanov
Valid Gahramanov
MHMichal Hameiri-Grossman
Michal Hameiri-Grossman
ESElena Shinderman-Maman
Elena Shinderman-Maman
EBEsther R. Berko
Esther R. Berko
Supplementary Figure S3: DNA methylation analysis of neuroblastoma tumor samples reveals distinct methylation patterns. (A) Genome-wide DNA methylation levels were calculated in 7 neuroblastoma tumor gDNA and 3 PBL pools of 10 individuals each revealed globally reduced levels in neuroblastoma. Analysis is represented by violin plots with orange and white dots drawn at the distribution medians and means respectively. (B) Hierarchical clustering analysis based on methylation levels in neuroblastoma tumor and PBL pool samples reveal distinct molecular characteristics.